Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Friday, May 08, 2020 5:52:33 AM
WHEN: Tuesday, May 12, 2020 12:00 pm - 1:00 pm
WHERE: Online via Zoom (details to be provided upon registration)
Register for the event now
About this event
Join us on Tuesday, May 12 at 12 p.m. ET, for an online discussion with Prof. Ruth Arnon, from Weizmann’s Department of Immunology, who has spearheaded a universal influenza vaccine.
As a renowned immunologist, Prof. Arnon previously co-developed a multiple sclerosis (MS) drug that commands a third of the market worldwide. She is now undergoing the third and final phase in the clinical trial process for an influenza vaccine, which would protect people from the flu for many years and against multiple strains. Results are expected later this year.
Since the flu changes every year, new vaccines continually have to be made and developed for the current strain. After working on this project for two decades, Prof. Arnon and colleagues now have a vaccine they believe will be ready to go public, upon approval from regulators.
The event and question and answer period will be moderated by Dr. Arthur Slutsky, Keenan Chair in Medicine at St. Michael’s Hospital and Professor of Medicine, Surgery and Biomedical Engineering at the University of Toronto. Dr. Slutsky also serves on the Weizmann Canada Board of Directors.
We are so grateful for your support and participation.
DATE | Tuesday, May 12, 2020
TIME | Join by 11:50 a.m. ET, presentation will begin at 12:00 p.m. ET (noon)
LOCATION | Online via Zoom (details to be provided upon registration)
Please note that turning on your video camera for the event is optional. We hope you will join us in the capacity in which you feel comfortable.
This is a free event, but space is limited.
https://www.weizmann.ca/events/could-the-flu-become-history-a-conversation-with-prof-ruth-arnon-on-may-12/
Hopefully new info will be available?
Recent BVXV News
- Form NT 20-F - Notification of inability to timely file Form 20-F • Edgar (US Regulatory) • 04/30/2024 08:06:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/16/2024 09:27:06 PM
- Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG • PR Newswire (US) • 04/10/2024 11:00:00 AM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 03/12/2024 08:17:13 PM
- Scinai leadership to attend BIO-Europe Spring 2024 • PR Newswire (US) • 03/12/2024 12:00:00 PM
- Scinai Welcomes Liat Halpert as Head of Business Development and Sales • PR Newswire (US) • 02/13/2024 12:00:00 PM
- Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds • PR Newswire (US) • 01/04/2024 09:01:00 PM
- Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule • PR Newswire (US) • 11/20/2023 12:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM